(Q46082296)

19 December 2017

title

Amylin reduces plasma glucagon concentration in cats (English)

1 reference

19 December 2017

1 reference

4

1 reference

19 December 2017

author name string

Daniela Furrer

series ordinal

1

1 reference

19 December 2017

K Kaufmann

series ordinal

2

1 reference

19 December 2017

Claudia E Reusch

series ordinal

3

1 reference

19 December 2017

publication date

18 March 2009

1 reference

19 December 2017

published in

The Veterinary Journal

1 reference

19 December 2017

volume

184

1 reference

19 December 2017

issue

2

1 reference

19 December 2017

page(s)

236-240

1 reference

19 December 2017

Animal models of type 2 diabetes: clinical presentation and pathophysiological relevance to the human condition

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2009.02.011

Guideline for management of postmeal glucose

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2009.02.011

Unresolved challenges with insulin therapy in type 1 and type 2 diabetes: potential benefit of replacing amylin, a second beta-cell hormone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2009.02.011

The human amylin analog, pramlintide, reduces postprandial hyperglucagonemia in patients with type 2 diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2009.02.011

Feline models of type 2 diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2009.02.011

Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2009.02.011

Effect of pramlintide on weight in overweight and obese insulin-treated type 2 diabetes patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2009.02.011

Islet amyloid, islet-amyloid polypeptide, and diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2009.02.011

Pancreatic amylin as a centrally acting satiating hormone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2009.02.011

Pathogenesis of feline diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2009.02.011

Pramlintide reduces postprandial glucose excursions when added to insulin lispro in subjects with type 2 diabetes: a dose-timing study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2009.02.011

Adjunctive therapy with the amylin analogue pramlintide leads to a combined improvement in glycemic and weight control in insulin-treated subjects with type 2 diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2009.02.011

Catheter replacement of the needle in percutaneous arteriography; a new technique

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2009.02.011

Pramlintide, a synthetic analog of human amylin, improves the metabolic profile of patients with type 2 diabetes using insulin. The Pramlintide in Type 2 Diabetes Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2009.02.011

Effects of pramlintide, an amylin analogue, on gastric emptying in type 1 and 2 diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2009.02.011

Islet amyloid polypeptide: pinpointing amino acid residues linked to amyloid fibril formation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2009.02.011

Amylin replacement with pramlintide as an adjunct to insulin therapy in type 1 and type 2 diabetes mellitus: a physiological approach toward improved metabolic control

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2009.02.011

Tissue expression and secretion of amylin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2009.02.011

Inhibition of insulin secretion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2009.02.011

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2009.02.011

Hyperglycaemia but not hyperlipidaemia causes beta cell dysfunction and beta cell loss in the domestic cat.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2009.02.011

10.1016/J.TVJL.2009.02.011

7 January 2021

Identifiers

DOI

1 reference

19 December 2017

PubMed ID

19299171

1 reference

19 December 2017